Guest Editor(s)
-
- Prof. Roger M. Phillips
- Department of Pharmacy, School of Applied Sciences, University of Huddersfield, United Kingdom.
Website | E-mail
-
- Prof. Godefridus J. (Frits) Peters
Amsterdam UMC, location VUMC, Laboratory Medical Oncology, Cancer Center, Amsterdam, The Netherlands.
Department of Biochemistry, Medical University of Gdansk, Gdansk, Poland.
Website | E-mail
Special Issue Introduction
The fate of a drug and its ability to exert a pharmacological effect is determined by many factors including its pharmacokinetic (PK) profile. Moreover, the PK of a drug can be modulated by pharmacogenetic (PG) properties, either systemic or of the tumor. Both PK and PG determine, ultimately, the concentration (C) of drug delivered to tumor cells and the duration (T) of drug exposure. Drug delivery to tumors is often impaired and PK resistance is an emerging but often overlooked issue in oncology. PK resistance effectively describes the impact that PG, biological, physiochemical, micro-environmental factors etc. have on drug delivery (C and T parameters) and is a major contributing factor to the problem of cancer drug resistance.
In this special issue we welcome papers focusing on how a drug’s PK or PG profile may lead to drug resistance. The issue is also open for papers that discuss how barriers to effective drug delivery to tumors can be overcome with the aim of identifying key challenges that need to be addressed if the impact that PK resistance on cancer therapy is to be reduced.
Submission Deadline
30 Sep 2022
Cancer Drug Resistance
